Background and purpose: This retrospective study evaluates the safety, effectiveness, and long-term clinical and angiographic follow-up of intracranial aneurysms treated with the Low-Profile Visualized Intraluminal Support Junior (LVIS Jr.) stent and parent vessels of diameter equal to or less than 2.5 mm.
Introduction
Treatment of intracranial aneurysms originating from distal vessels with small vessel diameter is challenging because of the high rate of periprocedural complications such as in-stent thrombosis and in-stent stenosis. 1, 2 The Low-Profile Visualized Intraluminal Support Junior (LVIS Jr.) stent is approved for unruptured, wide-necked (>4 mm or dome-to-neck ratio <2) intracranial aneurysms and recommended for parent vessels of less than 3.5 mm. This device is a low-profile, braided, self-expanding single, closed-cell construction of nickel/titanium (nitinol) material with compliant cells. We report our center's experience in regard to the feasibility, safety, and effectiveness of this device for the treatment of intracranial aneurysms with parent vessel diameter of 2.5 mm or less.
Material and methods

Patient population
This is a retrospective analysis with institutional review board approval of all patients who underwent stentassisted coil embolization with the LVIS Jr. stent for intracranial aneurysms with parent vessel diameter of We included the smallest diameter of the stented segment. We report aneurysm characteristics (location, dome and neck size) based on catheter angiography, all periprocedural complications, initial and follow-up angiographic results, and patient's clinical condition after treatment and during follow-up.
Endovascular treatment
All embolization procedures were performed with the patients under general endotracheal anesthesia on a biplane angiography system. Rotational angiography was performed for every case. A 6 F guide catheter was introduced through a femoral sheath into the internal carotid (ICA) or the vertebral artery. A Headway 17 or Headway Duo microcatheter (Microvention, CA) was used to deliver the LVIS Jr. in 31 and four patients, respectively. Forty-four stents were deployed (nine patients were treated with double stents with Y (n ¼ 8) or X (n ¼ 1) configuration. We measured changes in vessel anatomy before and after stenting using the angle-measuring tool from a picture archiving and communication system both in frontal and lateral projections. The same projections before and after stenting were utilized. The caliber was placed in the middle of the lumen. We report the largest change seen on either the frontal or lateral plane. In case of Y-stent we reported the most prominent change between the two vessels. Coil embolization of the aneurysms was carried out using a jailing technique in 17 patients (using the Headway 17 in 16 patients and Headway Duo in one patient), or through the interstices of the LVIS Jr. stent in 18 patients (using the Headway 17 in 15 patients and Headway Duo in three patients). Illustrative cases are seen in Figures 1 and 2 .
Periprocedural anticoagulation and antiplatelet management
For an unruptured aneurysm, dual-antiplatelet therapy (aspirin and clopidogrel or ticagrelor) was administered for four to seven days before the procedure. Heparin was titrated during the procedure to achieve an activated clotting time two to three times the baseline. In patients presenting with aneurysmal subarachnoid hemorrhage (SAH), the treatment was delayed for approximately seven days post-hemorrhage, and the patient was administered dual-antiplatelet therapy within 24 hours before the stent-assisted coiling procedure. Dual-antiplatelet therapy was continued for three to six months after the procedure and then aspirin was solely used. When in-stent thrombosis occurred during the procedure, patients received a weight-based, intracranial-arterial infusion of abciximab, followed by intravenous infusion for the next 12 hours.
Follow-up
The efficacy of aneurysm coiling was assessed with the modified Raymond and Roy scale, 3 where Class 1 represents complete aneurysm occlusion, Class 2 represents neck remnant, and Class 3 represents residual aneurysm. Class 3 further divides into Classes 3a and 3b, where 3a represents contrast within the coil mass and Class 3b represents contrast along the aneurysm wall. All patients were followed with contrast-enhanced magnetic resonance angiography (CE-MRA). Postprocedural digital subtraction angiography (DSA) follow-up was not performed since at our institution we use DSA only when MRA is not adequate or if there is need for re-treatment. In-stent stenosis was defined as equal to or greater than 50% diameter loss. Recanalization was defined when an initial complete aneurysm occlusion converted to a residual neck or a residual aneurysm or when an initial residual neck converted to a residual aneurysm. Two experienced interventional neuroradiologists reviewed all images and reached a consensus on angiographic results. Clinical outcome was assessed with the modified Rankin Scale (mRS).
Results
Study population
A total of 35 consecutive patients (22 women and 13 men) with 35 intracranial aneurysms were included in the analysis. The mean age was 59.7 (range, 29 to 77 years old). We were able to treat all patients as intended and all LVIS Jr. stents were successfully delivered to the target location. Two patients were lost to follow-up and four patients did not have any imaging follow-up since they were recently treated.
Aneurysm characteristics
The anterior circulation was the most common location (88.6%), with 14 anterior communicating artery (Acomm) aneurysms (45.1%), four proximal anterior cerebral artery (ACA) aneurysms (12.9%) and two distal ACA aneurysms (6.5%), and 11 middle cerebral artery (MCA) aneurysms (35.5%). Two aneurysms (5.7%) were located in the basilar tip: one (2.8%) at the vertebrobasilar junction and one (2.8%) at the posterior inferior cerebellar artery. Ten aneurysms were ruptured, nine remotely and one acutely. Of the ruptured group, nine were remotely ruptured and were treated at the time of rupture with coil embolization alone, and presented for treatment at a second stage with the LVIS Jr. stent for residual or recurrent aneurysm. Almost all aneurysms had a neck > 4 mm or dome-toneck ratio < 2 (n ¼ 34). One aneurysm had a relatively narrow neck but a stent was utilized as it was thought to be a dissecting aneurysm. The maximum sizes of the aneurysm dome varied from 1.8 to 13.5 mm (mean, 6.4 mm). The parent vessel diameter ranged from 0.9 to 2.5 mm (mean, 2.2 mm), with 15/35 aneurysms with parent vessel diameter of 2 mm or less.
There was an increased angle of the stented vessels (i.e. straightening) in 31 patients, with an average change of 19.8 degrees (range 0-50 degrees). There was no associated vessel dissection or impairment of flow.
Technical periprocedural complications
Intracranial-procedural in-stent thrombosis developed in four patients (11.4%). In three patients, the in-stent thrombosis occurred during the procedure. This was treated with an intra-arterial bolus of abciximab followed by a 12-hour intravenous drip of abciximab (two patients) or intra-arterial bolus of abciximab alone (one patient). In one patient, in-stent thrombosis developed six hours after the procedure. The patient was brought back to the angio suite and received intra-arterial abciximab with resolution of the thrombus; however, the patient had already developed an embolic stroke and had an mRS of 3 at discharge. This was the only patient with a permanent neurological deficit in our series. Of the four patients with in-stent thrombosis, two patients had MCA aneurysms that were treated with the ''Y'' configuration and one patient had an Acomm aneurysm that was treated with the ''Y'' configuration.
Intraprocedural aneurysm rupture occurred in one patient (2.8%). This patient had a perforation of the aneurysm while the aneurysm was accessed through the stent with the microcatheter and was treated with rapid coil embolization. The patient was neurologically intact after the event and the computed tomography (CT) scan showed minimal SAH with an mRS of 0 at sixmonth follow-up.
Neurological periprocedural complications
There was one permanent neurological deficit in a patient who developed in-stent thrombosis. Despite treatment with intra-arterial and intravenous abciximab, an ischemic stroke did occur resulting in permanent neurological deficit (mRS of 3 at discharge).
Three patients had a transient neurological deficit, including a transient episode of global aphasia, an episode of unresponsiveness, and one episode of word-finding difficulty after the procedure with a negative CT (n ¼ 3), computed tomography angiography (CTA) (n ¼ 2), and DSA (n ¼ 1). The deficits resolved within 12 hours without intervention and there was no recurrence. Neurological morbidity, defined as permanent neurological deficit as a result of the procedure, was 2.9%.
Follow-up
Clinical and angiographic results are summarized in Table 1 . Immediate complete aneurysm occlusion occurred in 21 out of 35 patients (60%), neck remnant in five out of 35 patients (14.3%), and residual aneurysm in nine out of 35 patients (25.7%). The angiographic follow-up ranged between four and 24 months (mean, 10.4 months). Two patients were lost to follow-up, and 4 patients did not reach the time point for follow-up imaging at the time of this analysis (recent treatment). Of the 21 patients with initial complete aneurysm occlusion, four patients developed neck remnants at last imaging follow-up. Of the five patients with neck remnants initially, one patient progressed to complete aneurysm occlusion, three patients stayed the same, and one patient did not have a follow-up. Of the nine patients with residual aneurysms initially, five patients progressed to complete aneurysm occlusion, two patients progressed to neck remnants, and two patients did not have a follow-up. Worsening occlusion rates were seen in three out of 29 (10.3%) patients with available follow-up imaging. Long-term angiographic follow-up (>12 months) was recorded in nine patients: Six of them had complete aneurysm occlusion (67%). There were no aneurysm ruptures during the follow-up period.
The clinical follow-up ranged between one and 25 months (mean, 10.5 months). Long-term clinical follow-up (>12 months) was recorded in 14 patients; all of them had an mRS of less than or equal to 2 (100%). The mRS at last follow-up was less than or equal to 2 in 94.3% of the patients. Two patients had an mRS of 3 at discharge: One patient had an embolic stroke from a delayed stent-related thrombus, and in the other case the patient had an mRS of 3 at baseline from a previous stroke of the left ACA territory. Instent stenosis occurred in one out of 29 patients (3.4%), who was asymptomatic. No deaths were observed.
Discussion
Our review of the literature on this topic included three papers that provide details of LVIS and LVIS Jr. stenting in parent vessels less than or equal to 2.5 mm in diameter (see Table 2 ). In our study, the initial complete aneurysm occlusion rate was 60%. The rate of initial complete aneurysm occlusion in the literature varies from 36.4% to 71.4%. [4] [5] [6] Wang et al. 4 reports an initial complete aneurysm occlusion rate of 36.4%. The low occlusion rate seen in this study might be related to the use of a 3.5 mm LVIS stent (which is different from the LVIS Jr. stent) on parent vessels with diameters of less than 2.5 mm. Owing to the different stent characteristics, the cells at the aneurysm neck may become wider thus decreasing the metal surface coverage and prevent denser coil packing. 4 We report complete occlusion of 72.4% at last angiographic follow-up (mean, 9.4 months), which is similar to the results by Wang et al. 4 , who reported an occlusion rate of 81.8% (mean, 8.3 months). Mo¨hlenbruch et al. 5 report an occlusion rate of 85.7% but they do not report the duration of followup. In our series, we have a 67% complete aneurysm occlusion at the long-term angiographic follow-up (>12 months). All previous reports have only shortterm and mid-term results with the LVIS Jr. stent.
2,4,5,7-11 (see Table 2 ). In addition, in our study approximately 56% of patients with initial residual aneurysms after placement of the LVIS Jr. stent progressed to complete aneurysm occlusion at last follow-up. This progression of occlusion might be explained by the possible flow-diverting properties of this type of stent. 12 Although the procedure-related complications were 14.2% (four in-stent thrombosis and one hemorrhage from aneurysm perforation), our morbidity rate was only 2.9%. We report four cases (11.4%) of in-stent thrombosis that completely resolved with abciximab. It's conceivable that the risk of in-stent thrombosis increases when stenting involves smaller parent vessel diameters and in particular when a ''Y'' and/or ''X'' configuration is used, as more metal coverage increases the risk of thrombosis. It is our current practice to put patients on heparin-drip prophylaxis for 12 hours when a ''Y'' and/or ''X'' configuration is used in aneurysms with small parent vessel diameter. According to Wang et al., 4 incomplete stent expansion with poor wall apposition are common causes of in-stent thrombosis. In their series, a 3.5 mm LVIS stent (not the LVIS Jr.) was used in parent vessels with diameters of less than 2.5 mm. According to the authors, this leads to an elongated stent and larger stent cells and therefore probably decreases the risk of in-stent thrombosis. 4 Feng et al. 6 report one case of an MCA bifurcation aneurysm with acute in-stent thrombosis that resolved after intravenous tirofiban injection without any neurological deficit. Mo¨hlenbruch et al. do not report any in-stent thrombosis in their series. 5 We had a hemorrhagic complication caused by perforation of an Acomm aneurysm by a microcatheter that was rapidly treated by placing coils into the aneurysm sac. The patient woke up neurologically intact without any long-term sequela. Wang et al. 4 reports an aneurysm perforation during coiling in a previously ruptured aneurysm. The patient had a complete aneurysm occlusion and did not develop any neurological deficits either. Mo¨hlenbruch et al. 5 reports two periprocedural complications, the first case was an ICA dissection caused by the guide catheter and the second case a partial stent opening with no clinical consequences.
Asymptomatic in-stent stenosis developed in one patient (3.4%). Wang et al. 4 reports asymptomatic instent stenosis in one case as well (4.5%).
The LVIS Jr. stent may offer greater conformability, apposition to the vessel wall, and stability than other, non-braided stents. During deployment, the stent can be expanded to protrude into the aneurysm neck in order to provide maximal neck coverage. The stent mesh gap is 1.5 mm and can be probed with the same microcatheter after stent deployment to fill the aneurysm with coils. The stent can be delivered via smallcaliber microcatheters such as the Headway Duo (Microvention) (0.53 mm outer diameter) and therefore can be used in distal, small-caliber vessels. The stent is compatible with a dual-lumen balloon microcatheter (Scepter C or XC, Microvention) and can be resheathed and repositioned even if up to 70%-80% of its length has been deployed.
There was variable straightening of the stented vessel in the majority of patients. Even though this phenomenon is to be expected with stents in such small vessels, we did not experience any related complications. The practitioner should be aware of this possibility and we recommend performing an angiogram immediately after stent deployment to assess for changes in anatomy of the parent vessel and the aneurysm (neck orientation, for example).
There are limitations of our study. First, this is a retrospective analysis with inherent limitations. Second, an independent core lab was not utilized to validate the angiographic results. Another limitation is that the procedures were performed by different physicians with some variability in technique and antiplatelet regimens. Lastly, the follow-up time points weren't uniform among patients.
Our paper represents the largest series of LVIS Jr. stent-assisted coil embolization in small parent vessels to date. In this cohort, we have reported on a minimal parent artery size of 0.9 mm, unfolding the potential of the device in experienced hands. The characteristics and safety profile of this device allowed us to treat distal complex aneurysms with acceptable risk.
Conclusion
Stenting with the LVIS Jr. stent allowed us to treat complex intracranial aneurysms with parent vessel diameter of 2.5 mm or less with an acceptable safety profile.
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